To Evaluate The Effects Of SB-649868 (10, 30 Mg And 60 Mg) On Subjects With Primary Insomnia
NCT00426816
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
48
Enrollment
INDUSTRY
Sponsor class
Conditions
Sleep Initiation and Maintenance Disorders
Interventions
DRUG:
SB-649868
DRUG:
Placebo
Sponsor
GlaxoSmithKline